Atezolizumab in Patients with Pretreated Urothelial Cancer: a Korean Single-Center, Retrospective Study

PURPOSE: Treatment targeting immune checkpoint with programmed death-1 (PD-1)/programmed death-ligand 1 (PD-L1) inhibitors has demonstrated efficacy and tolerability in the treatment of metastatic urothelial carcinoma (mUC). We investigated the efficacy and safety of atezolizumab in mUC patients who...

Descripció completa

Guardat en:
Dades bibliogràfiques
Publicat a:Cancer Res Treat
Autors principals: Hur, Joon Young, Kim, Youjin, Kwon, Ghee-Young, Kang, Minyong, Sung, Hyun Hwan, Jeon, Hwang Gyun, Jeong, Byong Chang, Seo, Seong Il, Jeon, Seong Soo, Lee, Hyun Moo, Lee, Su Jin, Park, Se Hoon
Format: Artigo
Idioma:Inglês
Publicat: Korean Cancer Association 2019
Matèries:
Original Article
Accés en línia:https://ncbi.nlm.nih.gov/pmc/articles/PMC6790849/
https://ncbi.nlm.nih.gov/pubmed/30653744
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.4143/crt.2018.604
Etiquetes: Afegir etiqueta
Sense etiquetes, Sigues el primer a etiquetar aquest registre!

Ítems similars